newsfilter
← Latest News
PR Newswire·

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

  • Nanyang Biologics Pte. Ltd. (NYB), an AI-driven drug discovery company backed by The9 Limited, secured shareholder approval for a business combination with RF Acquisition Corp II at an extraordinary general meeting on August 19, 2026.
  • The transaction aims to list NYB on the Nasdaq under the ticker symbol "NYB" following the approval vote.
  • The9 holds a strategic equity stake in NYB through its subsidiary Gamenow.net (Hong Kong) Limited and is expected to retain approximately 15% to 16% ownership of the combined public company upon completion.
  • NYB utilizes its proprietary Vecura™ AI platform, built on a library of over one million natural compounds, to identify novel bioactive drug candidates overlooked by conventional synthetic-first methods.
  • George Lai, CEO of The9, cited the vote as a strong indicator of shareholder confidence in NYB's business model.
  • The9 views this investment as a key component of its strategy to expand beyond its core gaming ecosystem into broader AI-driven sectors.